Shandong Xinhua Pharmaceutical subsidiary obtained the registration certificate for ursodeoxycholic acid capsules.
Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. (referred to as "...")
Shandong Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. (referred to as "Xinda Pharmaceutical") has received the "Drug Registration Certificate" issued by the National Medical Products Administration for ursodeoxycholic acid capsules. This drug is used to treat gallbladder cholesterol stones (must be stones that can be penetrated by X-rays, and the gallbladder contraction function must be normal); cholestatic liver disease (such as: primary biliary cirrhosis); and bile reflux gastritis.
Related Articles

MINSHENG EDU (01569): HKIAC makes a partial ruling ordering the respondent to fulfill the relevant terms of the SPA.

BRAINAURORA-B (06681) signs a brain health digital AI technology service cooperation agreement with Macau Mirror Lake Hospital.

China Securities Co., Ltd.: The spring market is expected to continue after the Spring Festival, it is recommended to hold onto stocks during the festival.
MINSHENG EDU (01569): HKIAC makes a partial ruling ordering the respondent to fulfill the relevant terms of the SPA.

BRAINAURORA-B (06681) signs a brain health digital AI technology service cooperation agreement with Macau Mirror Lake Hospital.

China Securities Co., Ltd.: The spring market is expected to continue after the Spring Festival, it is recommended to hold onto stocks during the festival.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


